AM-Pharma closes €12.2m financing round

New capital to complete Phase II development of recAP in Acute Kidney Injury Bunnik, The Netherlands, 11 September 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces that it has closed a €12.2 million financing round led by Gilde Healthcare. Existing investors AbbVie, BB […]

AM-Pharma announces positive Phase I data on recAP for Acute Kidney Injury

Bunnik, The Netherlands, 26 March 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which demonstrate that recAP is safe and well tolerated at all doses. In total 50 healthy […]

American Journal of Kidney Disease publishes review article of Alkaline Phosphatase

Leading journal presents case for AM-Pharma product to treat sepsis-associated acute kidney injury. Bunnik, The Netherlands, 28 January 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces that the American Journal of Kidney Disease has published an In Translation feature entitled: Alkaline phosphatase: a […]

AM-Pharma presents positive data from recAP preclinical study at ASN meeting

Bunnik, The Netherlands; Atlanta, GA, 8 November 2013. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, today presents preclinical data on its drug candidate recAP in an Acute Kidney Injury (AKI) setting, at the American Society of Nephrology (ASN) meeting Kidney Week in Atlanta, GA, […]

AM-Pharma returns to clinic with Phase I trial of new recombinant human Alkaline Phosphatase

AM-Pharma returns to clinic with Phase 1 trial of new recombinant human Alkaline Phosphatase to treat Acute Kidney Injury. Trial to reaffirm safety seen in previous Phase I & II trials of bovine Alkaline Phosphatase. Bunnik, The Netherlands, 23 September 2013. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase […]

AM‐Pharma Announces Appointment of Industry Expert Guido Magni as Board Member

Bunnik, The Netherlands, 16 March 2012. AM‐Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of recombinant human Alkaline Phosphatase (AP) for treatment of Acute Kidney Injury and inflammatory bowel diseases, has appointed Dr Guido Magni as a member of its Supervisory Board. Dr Magni MD PhD was trained as an MD […]

AM-Pharma Announces Appointment of Russell Greig as Chairman

Bunnik, The Netherlands, 4 January 2012. AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of recombinant human Alkaline Phosphatase (AP) for treatment of Acute Kidney Injury and Inflammatory bowel diseases, today announced the appointment of Dr Russell Greig as Chairman of the Supervisory Board. Dr Greig served nearly three decades with […]

AM-Pharma Raises €29.2m in Series D Financing

Bunnik, The Netherlands, 13 September 2011. AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) for  treatment of severe inflammatory diseases, today announced that it has raised €29.2m in Series D financing. The series D round was led by Ysios Capital Partners, co-led by Kurma Life Science Partners […]

AM-Pharma appoints Erik van den Berg as CEO

Bunnik, The Netherlands, 2 September 2011. AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) for the treatment of severe inflammatory diseases, today announced the appointment of Erik van den Berg, previously VP Business Development of AM-Pharma as CEO of the company. Bart Wuurman, who has led the […]

AM-Pharma presents positive results of its Phase II clinical trial with Alkaline Phosphatase in Acute Kidney Injury

Alkaline Phosphatase improved renal function, reduced length of stay in Intensive Care, and could become First-in-Class drug in multi-billion market Bunnik, The Netherlands, 10 March 2010. AM-Pharma B.V., the biopharmaceutical company, today announced positive results from its Phase II Acute Kidney Injury trial with Alkaline Phosphatase at ISICEM, one of the world’s leading Intensive Care […]